A citation-based method for searching scientific literature

T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
Times Cited: 193



Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Times Cited: 348




List of shared articles



Times cited

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2021
11

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li, Fei Xie. Front Public Health 2021
0

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lei Tian, Yuzi Cai, Huijuan Zheng, Sinan Ai, Mengqi Zhou, Qian Luo, Jingyi Tang, Weijing Liu, Yaoxian Wang. Front Pharmacol 2021
0

Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Ayodele Odutayo, Bruno R da Costa, Tiago V Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A Hincapié, Aquila Akingbade, Myanca Rodrigues,[...]. J Am Heart Assoc 2021
0

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.
E G Dorsey-Treviño, J G González-González, N Alvarez-Villalobos, V González-Nava, B M Contreras-Garza, A Díaz González-Colmenero, G Rodríguez-Tamez, F J Barrera-Flores, A M Farrell, V M Montori,[...]. J Endocrinol Invest 2020
8



Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
16


Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
6

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
14

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
24

No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han, Linong Ji. J Diabetes Investig 2018
28

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Xiaoling Cai, Wenjia Yang, Xueying Gao, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji. Obesity (Silver Spring) 2018
45

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Samuel Seidu, Setor K Kunutsor, Xavier Cos, Syed Gillani, Kamlesh Khunti. Prim Care Diabetes 2018
37


Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
14


SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Huilin Tang, Qi Dai, Weilong Shi, Suodi Zhai, Yiqing Song, Jiali Han. Diabetologia 2017
53

The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia. Indian J Endocrinol Metab 2017
0